Enzalutamide

Generic Name
Enzalutamide
Brand Names
Xtandi, Enzalutamide Viatris
Drug Type
Small Molecule
Chemical Formula
C21H16F4N4O2S
CAS Number
915087-33-1
Unique Ingredient Identifier
93T0T9GKNU
Background

Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...

Indication

Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.

Associated Conditions
Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Associated Therapies
-
Clinical Trials
Related News

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

First Posted Date
2022-01-13
Last Posted Date
2022-08-05
Lead Sponsor
Nuvation Bio Inc.
Registration Number
NCT05191017
Locations
🇺🇸

Pennsylvania Cancer Specialists and Research Institute, Gettysburg, Pennsylvania, United States

🇺🇸

Gabrail Cancer Center Research, Canton, Ohio, United States

🇺🇸

NEXT Virginia, Fairfax, Virginia, United States

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

First Posted Date
2021-11-09
Last Posted Date
2024-12-13
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
49
Registration Number
NCT05112965
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, China

🇨🇳

Tianjin Cancer Hospital, Tianjin, China

🇨🇳

Zhongshan Hospital Fudan University, Shanghai, China

and more 16 locations

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

First Posted Date
2021-10-18
Last Posted Date
2024-06-20
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
30
Registration Number
NCT05081193
Locations
🇺🇸

Allegheny Health Network, Pittsburgh, Pennsylvania, United States

🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

Phase 1
Active, not recruiting
Conditions
Prostate Cancer
Interventions
Drug: EPI-7386 with Enzalutamide
Drug: Enzalutamide
First Posted Date
2021-10-13
Last Posted Date
2024-11-12
Lead Sponsor
ESSA Pharmaceuticals
Target Recruit Count
150
Registration Number
NCT05075577
Locations
🇺🇸

Arizona Urology, Tucson, Arizona, United States

🇺🇸

Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 21 locations

Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

First Posted Date
2021-09-08
Last Posted Date
2024-11-14
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
8
Registration Number
NCT05037500
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

First Posted Date
2021-08-18
Last Posted Date
2023-09-15
Lead Sponsor
Rahul Aggarwal
Target Recruit Count
36
Registration Number
NCT05011188
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

First Posted Date
2021-08-02
Last Posted Date
2024-04-17
Lead Sponsor
Zenith Epigenetics
Target Recruit Count
200
Registration Number
NCT04986423
Locations
🇺🇸

Hematology Oncology Clinic, Baton Rouge, Louisiana, United States

🇺🇸

Messino Cancer Center, Asheville, North Carolina, United States

🇨🇳

Hubei Cancer Hospital, Wuhan, Hubei, China

and more 21 locations

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

First Posted Date
2021-06-22
Last Posted Date
2024-06-11
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
186
Registration Number
NCT04934722
Locations
🇨🇳

Zhejiang Provincial People's Hospital ( Site 0809), Hangzhou, Zhejiang, China

🇨🇳

The First Affiliated Hospital of Wenzhou Medical University ( Site 0834), Wenzhou, Zhejiang, China

🇨🇳

The first affiliated Hospital of Xi an Jiaotong University ( Site # 0812), XI An, Shanxi, China

and more 21 locations

Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

First Posted Date
2021-01-28
Last Posted Date
2024-12-13
Lead Sponsor
Astellas Pharma Global Development, Inc.
Target Recruit Count
100
Registration Number
NCT04729114
Locations
🇺🇸

Northwest Medical Specialties, Tacoma, Washington, United States

🇺🇸

First Urology, Jeffersonville, Indiana, United States

🇺🇸

Garden Sate Urology, Morristown, New Jersey, United States

and more 12 locations

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

First Posted Date
2020-12-01
Last Posted Date
2024-11-01
Lead Sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Target Recruit Count
415
Registration Number
NCT04647526
Locations
🇺🇸

VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

🇺🇸

Greater Dayton Cancer Center, Kettering, Ohio, United States

🇺🇸

Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States

and more 51 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy